Investor profile
Pureos Bioventures has backed 8 European tech companies across 9 funding rounds between 2018 and 2024, joining rounds totalling €207M. Most active in Healthtech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Citryll | Netherlands | 1 | €85M |
| Araris Biotech | Switzerland | 2 | €38M |
| Memo Therapeutics | Switzerland | 1 | €26M |
| MinervaX | Denmark | 1 | €22M |
| Engimmune Therapeutics | Switzerland |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Citryll | Series B | €85M | 2024-12 |
| Memo Therapeutics | Series C | €26M | 2023-11 |
| Araris Biotech | Other | €24M | 2022-10 |
| MinervaX |
| 1 |
| €15M |
| Alentis Therapeutics | Switzerland | 1 | €11M |
| NovaGo Therapeutics | Switzerland | 1 | €8.9M |
| Corlieve Therapeutics | France | 1 | €0 |
| Other |
| €22M |
| 2022-12 |
| Engimmune Therapeutics | Seed | €15M | 2022-05 |
| Araris Biotech | Seed | €14M | 2020-10 |
| Alentis Therapeutics | Series A | €11M | 2019-04 |
| NovaGo Therapeutics | Series A | €8.9M | 2019-01 |
| Corlieve Therapeutics | Seed | €0 | 2020-11 |
